Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Leukemia, Myeloid, Acute 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 40Myelodysplastic Syndromes 40Multiple Myeloma 34Lymphoma 32Leukemia 28Lymphoma, Non-Hodgkin 27Leukemia, Lymphocytic, Chronic, B-Cell 24Hodgkin Disease 21Leukemia, Myelogenous, Chronic, BCR-ABL Positive 20Hematologic Neoplasms 17Lymphoma, Large B-Cell, Diffuse 16Primary Myelofibrosis 11Neoplasms, Plasma Cell 10Leukemia, Myelomonocytic, Chronic 10Lymphoma, Follicular 9Graft vs Host Disease 9Myeloproliferative Disorders 8Neuroblastoma 7Leukemia, Myelomonocytic, Juvenile 7Lymphoma, Mantle-Cell 6Breast Neoplasms 6Recurrence 5Neoplasms 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Biphenotypic, Acute 5Wilms Tumor 4Rhabdoid Tumor 4Polycythemia Vera 4Lymphoma, T-Cell 4

Interventions

3-Iodobenzylguanidine 8anlotinib 4Temozolomide 4lutetium Lu 177 dotatate 3Phenoxybenzamine 3Everolimus 3pegfilgrastim 2cabozantinib 2Granulocyte Colony-Stimulating Factor 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Adrenalectomy 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vatalanib 1vandetanib 1temsirolimus 1pentetreotide 1penpulimab 1pembrolizumab 1olaparib 1lenvatinib 1lanreotide 1gallium Ga 68 dotatate 1fluorodopa F 18 1fludarabine phosphate 1belzutifan 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pheochromocytoma × Stem Cell Transplantation × Clear all
NCT01850888 2025-12-18

MIBG for Refractory Neuroblastoma and Pheochromocytoma

Masonic Cancer Center, University of Minnesota

Phase NA Completed
15 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡